interstiti
lung
diseas
ild
gener
character
accumul
inflammatori
cell
within
lung
follow
progress
deposit
extracellular
matrix
subsequ
destruct
alveolar
airspac
precis
role
inflammatori
cell
pathogenesi
ild
remain
poorli
understood
although
evid
indic
lymphocyt
play
import
role
initi
develop
pulmonari
fibrosi
howev
studi
evalu
prognost
signific
lymphocyt
subset
patient
nonspecif
interstiti
pneumonia
nsip
therefor
hypothes
patient
nsip
respond
success
corticosteroid
therapi
harbor
differ
lymphocyt
subpopul
compar
patient
respond
test
hypothesi
evalu
distribut
lymphocyt
subset
lung
tissu
patient
nsip
use
immunohistochemistri
quantifi
lymphocyt
subset
present
lymphoid
follicl
well
perivascular
interstiti
peribronchi
region
explor
relationship
prognosi
surviv
april
decemb
patient
peke
union
medic
colleg
hospit
pumch
diagnos
nsip
accord
analysi
lung
biopsi
fiftyf
patient
complet
followup
undergo
test
pulmonari
function
test
comput
tomographi
ct
chest
includ
studi
nsip
diagnos
accord
american
thorac
societi
at
european
respiratori
societi
consensu
classif
patient
treat
corticosteroid
immunosuppress
undergo
lung
biopsi
connect
tissu
diseas
ctd
diagnos
accord
criteria
american
colleg
rheumatolog
follow
autoantibodi
nucleu
ana
titer
rheumatoid
factor
ssyndromerel
antigen
ssa
ssb
sm
ribonucleoprotein
cyclic
citrullin
peptid
patient
nsip
classifi
group
follow
member
ctdnsip
group
met
criteria
american
colleg
rheumatolog
ctd
member
nsipab
group
least
one
posit
serolog
test
member
group
autoantibodi
neg
extract
clinic
characterist
document
time
patient
first
visit
follow
age
ethnic
sex
symptom
cough
dyspnea
wheez
time
lung
biopsi
symptom
sign
ctd
smoke
statu
physic
examin
find
pulmonari
function
result
serolog
result
chest
ct
scan
inform
consent
use
medic
record
obtain
everi
patient
guardian
patient
admit
hospit
pumch
institut
review
board
approv
studi
refer
number
ethic
approv
spirometri
total
lung
capac
determin
use
plethysmographi
forc
vital
capac
fvc
diffus
capac
lung
carbon
monoxid
measur
accord
at
recommend
result
express
percentag
predict
normal
valu
prognosi
describ
accord
fvc
year
steroid
therapi
classifi
patient
follow
fvcgroup
improv
fvc
fvcgroup
improv
fvc
fvcgroup
fvc
reduc
greater
patient
underw
highresolut
ct
hrct
chest
upon
initi
evalu
radiologist
special
diffus
parenchym
lung
diseas
review
ct
scan
extent
preval
abnorm
measur
area
follow
lung
apex
carina
carina
upper
pulmonari
vein
upper
pulmonari
vein
base
lung
hrct
imag
assess
determin
extent
parenchym
abnorm
includ
groundglass
opac
ggo
reticul
honeycomb
consolid
emphysema
extent
abnorm
determin
use
scale
six
zone
prognosi
describ
accord
manifest
detect
use
ct
year
steroid
therapi
patient
nsip
classifi
follow
ctgroup
improv
ggo
reticular
opac
group
ctgroup
lesion
reduc
ctgroup
lesion
reduc
two
experienc
pathologist
review
independ
lung
biopsi
specimen
histolog
pattern
assign
accord
consensu
opinion
pathologist
unawar
patient
clinic
inform
histolog
pattern
patient
classifi
accord
criteria
propos
katzenstein
fiorelli
cellular
mix
fibrot
small
airway
defin
intern
diamet
mm
without
cartilag
airway
wall
small
blood
vessel
defin
intern
diamet
lung
biopsi
specimen
fix
neutralbuff
formalin
cut
slice
embed
paraffin
cut
section
paraffin
section
react
clone
zeta
clone
zeta
antibodi
use
labeledstreptavidinbiotin
complex
method
section
deparaffin
rehydr
trisbuff
salin
tb
tri
nacl
ph
min
treat
hydrogen
peroxid
min
inhibit
endogen
peroxidas
activ
wash
tb
incub
primari
antibodi
h
immunohistochem
analys
express
perform
use
tissu
section
number
darkbrown
cell
determin
use
nanozoom
slide
scan
system
hamamatsu
photon
kk
japan
tokyo
anymicro
dss
pro
imag
analysi
system
yu
tian
shi
ji
wei
ye
inc
beij
china
follicl
well
perivascular
interstiti
peribronchi
region
analyz
imag
lymphocyt
obtain
region
slide
least
six
highpow
field
magnif
analysi
area
approxim
randomli
select
region
use
count
stain
cell
fig
patient
receiv
standard
initi
cours
oral
prednison
start
mgkgd
month
taper
everi
week
mgd
decreas
initi
dose
everi
week
maintain
mgd
patient
treat
month
cyclophosphamid
administ
concurr
steroid
therapi
oral
dose
mgd
administ
month
patient
diagnos
ctdnsip
patient
underw
routin
examin
everi
month
lung
biopsi
year
interstiti
lung
diseas
clinic
pumch
valu
express
mean
standard
deviat
sd
normal
distribut
data
evalu
use
test
wilcoxon
test
use
compar
two
nonnorm
distribut
valu
respect
fisher
exact
test
use
determin
differ
group
correl
coeffici
calcul
use
spearman
rank
method
cox
multivari
regress
analysi
use
evalu
risk
factor
surviv
time
overal
surviv
calcul
use
method
probabl
valu
obtain
use
test
statist
signific
defin
p
spss
spss
window
version
spss
inc
chicago
il
usa
use
statist
analysi
clinic
radiolog
physiolog
measur
obtain
time
initi
visit
shown
tabl
mean
age
patient
year
rang
year
patient
women
nonsmok
six
former
smoker
two
current
smoker
mean
durat
respiratori
symptom
onset
lung
biopsi
month
month
rang
month
patient
follow
mean
durat
month
rang
month
patient
diagnos
follow
ctdnsip
includ
seven
polymyositisdermatomyos
seven
rheumatoid
arthriti
four
syndrom
two
system
sclerosi
one
microscop
polyangi
nsipab
nsipab
differ
among
three
group
accord
age
sex
cough
dyspnea
symptom
arthralgia
raynaud
phenomenon
skin
rash
dri
eye
mouth
highli
associ
ctdnsip
nsipab
group
compar
nsipab
group
tabl
differ
among
three
group
note
arteri
blood
ga
hrct
find
abnorm
pulmonari
function
similar
among
three
group
character
restrict
defect
impair
diffus
tabl
followup
three
patient
cellular
nsip
die
two
lung
infect
one
liver
failur
six
four
patient
mix
fibrot
nsip
respect
die
progress
lung
diseas
distribut
lymphocyt
shown
fig
number
lymphocyt
per
follicl
perivascular
interstiti
peribronchi
region
respect
number
cell
decreas
gradual
order
follicl
perivascular
interstiti
peribronchi
region
differ
cell
count
two
differ
region
statist
signific
p
distribut
lymphocyt
fig
similar
lymphocyt
number
lymphocyt
per
perivascular
interstiti
peribronchi
region
significantli
differ
p
number
lymphocyt
follicl
much
greater
three
region
p
analyz
nsip
subtyp
follow
cellular
mix
five
fibrot
distribut
lymphocyt
subtyp
summar
tabl
perivascular
infiltr
lymphocyt
promin
patient
cellular
pattern
compar
mix
fibrot
pattern
signific
differ
number
infiltr
lymphocyt
among
four
anatom
region
number
lymphocyt
cell
ctdnsip
n
nsipab
n
nsipab
n
group
significantli
differ
four
anatom
region
tabl
undergo
therapi
year
patient
cellular
five
mix
pattern
achiev
improv
ggo
reticular
opac
ctgroup
lesion
patient
mix
pattern
decreas
ctgroup
lesion
patient
nine
mix
five
fibrot
pattern
reduc
ctgroup
number
lymphocyt
perivascular
tissu
ctgroup
significantli
greater
compar
two
ctgroup
vs
p
vs
p
fig
anatom
region
correl
number
lymphocyt
improv
hrct
find
cox
multivari
regress
analysi
reveal
month
followup
fvc
independ
factor
surviv
hr
ci
p
addit
file
tabl
margin
correl
fvc
number
perivascular
cell
fig
among
patient
cellular
mix
pattern
achiev
improv
fvc
fvcgroup
correl
perivascular
infiltr
dlco
first
visit
addit
file
figur
dlco
month
follow
addit
file
figur
nineteen
patient
eight
cellular
nine
mix
two
fibrot
pattern
achiev
improv
fvc
fvcgroup
fvc
valu
patient
three
cellular
nine
mix
three
fibrot
pattern
decreas
greater
fvcgroup
number
lymphocyt
infiltr
perivascular
tissu
fvcgroup
significantli
greater
two
group
vs
p
vs
p
fig
densiti
lymphocyt
infiltr
anatom
compart
significantli
associ
pulmonari
function
test
cox
multivari
regress
analysi
consid
age
sex
number
lymphocyt
infiltr
lung
lung
function
test
first
visit
year
followup
result
reveal
perivascular
infiltr
lymphocyt
hr
ci
p
independ
factor
surviv
addit
file
tabl
densiti
lymphocyt
infiltr
perivascular
tissu
patient
significantli
associ
surviv
time
r
p
fig
compar
anatom
compart
patient
much
higher
densiti
lymphocyt
perivascular
compart
surviv
longer
logrank
test
p
fig
cutoff
valu
determin
use
roc
curv
auc
patient
surviv
sensit
specif
densiti
lymphocyt
infiltr
anatom
compart
significantli
associ
surviv
time
import
find
present
studi
number
lymphocyt
infiltr
perivascular
tissu
correl
significantli
prognosi
nsip
immunohistochem
analys
reveal
lymphocyt
subset
infiltr
lymphoid
follicl
interstiti
region
perivascular
peribronchi
region
well
consist
find
previou
studi
studi
detect
signific
differ
lymphocyt
densiti
among
cellular
mix
fibrot
pattern
among
tissu
analyz
small
number
patient
fibrot
pattern
might
account
find
although
show
lymphocyt
patient
cellular
fibrot
pattern
contrast
present
studi
found
correl
infiltr
perivascular
tissu
cell
prognosi
predictor
prognosi
patient
ild
result
pulmonari
function
test
allcaus
mortal
present
studi
combin
analyz
perivascular
lymphocyt
infiltr
clinic
prognosi
fvc
consist
predict
mortal
patient
ipf
consid
best
marker
chronic
diseas
progress
fvc
data
serv
prefer
primari
endpoint
trial
therapi
ipf
present
studi
show
fvc
independ
predictor
surviv
consist
result
previou
studi
classifi
patient
accord
chang
fvc
followup
found
higher
number
perivascular
lymphocyt
correl
improv
fvc
present
studi
allcaus
mortal
cox
multivari
regress
analysi
reveal
perivascular
lymphocyt
infiltr
independ
predictor
surviv
surviv
time
correl
number
perivascular
lymphocyt
patient
higher
number
perivascular
lymphocyt
perivascular
region
better
prognosi
accumul
lymphocyt
tissu
consid
cellmedi
immun
reaction
bodili
injuri
particularli
patient
immun
dysfunct
accumul
perivascular
lymphocyt
occur
patient
cutan
lichen
planu
muscl
tissu
patient
dermatomyos
studi
found
cell
might
involv
pathogenesi
interstiti
lung
diseas
exampl
level
bronchoalveolar
lavag
fluid
indic
lung
fibroblast
induc
immun
respons
patient
nsip
anim
model
lung
injuri
perivascular
lymphocyt
accumul
lung
tissu
patient
interstiti
pneumonia
caus
graftversushost
diseas
interstiti
pneumon
develop
primarili
dissemin
perivascular
lymphocyt
infiltr
immunosuppress
agent
cyclophosphamid
suppress
inflamm
caus
perivascular
lymphocyt
reduc
lymphocyt
popul
amelior
lymphocyt
function
find
taken
togeth
present
studi
suggest
perivascular
infiltr
lymphocyt
contribut
pathogenesi
nsip
cell
involv
ild
treat
patient
antit
cellspecif
immunosuppress
antibodi
may
justifi
exampl
patient
ild
particularli
ctdild
respond
agent
unlik
lung
biopsi
perform
sole
count
tcell
pulmonari
function
test
less
invas
measur
avail
implic
find
relat
therapi
provid
answer
question
antit
cell
treatment
benefici
patient
ild
recogn
studi
limit
retrospect
design
b
lymphocyt
inflammatori
cell
investig
howev
knowledg
first
studi
evalu
relationship
perivascular
infiltr
cell
prognosi
patient
nsip
conclus
show
perivascular
infiltr
cell
correl
significantli
prognosi
surviv
underli
mechan
requir
studi
